[Liraglutide improves cardiac structure and function in mice with advanced diabetic nephropathy and massive proteinuria].
Nan Fang Yi Ke Da Xue Xue Bao · 2026
Last updated 2026-07-22| Journal | Nan Fang Yi Ke Da Xue Xue Bao, 2026 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
Abstract
OBJECTIVES: To investigate the effects of liraglutide on cardiac structure and function in a mouse model of diabetic nephropathy at the massive proteinuria stage.
METHODS: Twenty 12-week-old male spontaneous type 2 diabetic KKAy mice were fed a high-fat diet for 10 weeks to establish diabetic models with massive proteinuria, which were then randomly divided into diabetic model group and liraglutide treatment group, with 10 age-matched C57BL/6J mice fed a standard chow diet serving as the normal control group. After 8 weeks of intervention, cardiac structural and functional parameters of the mice were evaluated using echocardiography, and myocardial histopathological changes were observed with HE staining, Masson's trichrome staining, Sirius red staining, and transmission electron microscopy. Serum levels of cardiac-related indicators were measured, and the mRNA and protein levels of collagen I and collagen III were determined using RT-qPCR and Western blotting, respectively.
RESULTS: The diabetic mouse models showed significantly elevated blood glucose and increased body weight (<0.05) with disordered myocardial fibers, severe interstitial and perivascular fibrosis, and markedly upregulated myocardial expressions of collagen I and collagen III. Echocardiography revealed significantly increased left ventricular wall thickness, interventricular septal thickness, and left ventricular mass, reduced left ventricular internal diameter, decreased LVEF, FS, FAC, and the E/A ratio, and prolonged IVRT in the mouse models. Liraglutide treatment significantly improved these pathologies and alleviated cardiac functional impairment in the diabetic mice.
CONCLUSIONS: Mice with diabetic nephropathy and massive proteinuria exhibit left ventricular hypertrophy and reduced cardiac function, accompanied by prominent myocardial interstitial fibrosis and inflammatory responses. Liraglutide improves cardiac structural and functional impairments in these mice possibly by alleviating myocardial fibrosis and inflammatory responses.
Verbatim abstract via PubMed 42198969 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.